Présentation de l'entreprise
SciSparc Ltd. operates as a clinical-stage pharmaceutical entity focused on advancing drug development programs centered on cannabinoid therapies for specific neurological and psychiatric conditions. The company functions within the broader healthcare sector, specifically the biotechnology industry, where it pursues the creation of novel treatments for disorders such as Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and epilepsy. At the time of the last available data, the organization maintained a market capitalization of 1.93 million dollars and reported trailing twelve-month revenue of 1.31 million dollars while employing just two individuals. These financial figures indicate that SciSparc Ltd. represents a micro-cap entity with minimal operational scale, suggesting that its revenue generation is highly concentrated relative to its extremely small workforce, a common characteristic in early-stage biotechnology firms where capital is predominantly allocated toward research and development rather than commercial expansion or large-scale production.
Santé financière
The company reported trailing twelve-month revenue of 1.31 million dollars, yet it recorded a net income loss of 6.48 million dollars and an EBITDA of minus 7.029 million dollars. The substantial gap between positive revenue and significant negative net income reveals a cost structure dominated by high operating expenses typical of clinical-stage biotechnology, where research, development, and clinical trial costs far exceed current sales generated. Although the free cash flow is listed as not available, the reported negative EBITDA and net income imply that the company is burning cash to fund its pipeline rather than generating positive cash flow from operations. The gross margin stands at 38.7%, which is a positive indicator for the cost of goods sold relative to revenue, but the operating margin is a staggering minus 569.5%, and the profit margin is 0.0%, highlighting that the company is operating at a severe loss on an operating basis before non-operating items. When comparing liquidity, the company holds no debt and the cash on hand is not available, resulting in a debt-to-equity ratio that is not available, yet the absence of debt suggests a conservative balance sheet structure despite the lack of liquid cash reserves. The current ratio is not available, preventing a direct assessment of short-term liquidity coverage against liabilities, but the zero debt position mitigates immediate refinancing risks. Furthermore, the return on equity is minus 1,281.5% and the return on assets is not available, metrics that collectively reveal that management has not yet generated returns on shareholder capital or assets, reflecting the speculative nature of investing in a company with no profitable track record yet.
Évaluation de la valorisation
SciSparc Ltd. exhibits a trailing twelve-month price-to-earnings ratio of 0.00 due to its net losses, while the forward P/E ratio is not available, implying that future earnings estimates have not yet been calculated or are not expected to be positive in the near term. The price-to-book ratio is valued at 0.02, indicating that the market prices the company's equity at a fraction of its book value, which suggests the market assigns a low premium to its assets, likely due to the high intangible nature of biotechnology intellectual property and the risk associated with clinical-stage development. Alternative valuation metrics include a price-to-sales ratio of 1.48 and an enterprise value-to-EBITDA that is not available; the price-to-sales figure suggests that the market is valuing the company primarily on its revenue potential rather than profitability, which is standard for firms that have not yet achieved commercial success. The stock has traded between a 52-week low of 3.32 dollars and a 52-week high of 94.50 dollars, demonstrating extreme volatility within this trading range. Without a specific current price provided in the available facts to calculate the exact percentage, the range itself highlights the significant price discovery process ongoing for the stock. The beta value is 1.33, which indicates that the stock's price volatility is 33% higher than the broader market, suggesting that the security is significantly more sensitive to market fluctuations than large-cap equities.
Growth & Income
The revenue growth year-over-year is not available, and the earnings growth year-over-year is also not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue. As the company does not distribute dividends, the dividend yield is not available and the payout ratio is 0.0%, meaning the entity reinvests all available resources, including retained earnings, back into its drug development programs and operational infrastructure rather than providing income to shareholders. This reinvestment strategy is typical for clinical-stage pharmaceutical companies that prioritize advancing their pipeline of cannabinoid therapies over providing current returns. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, positioning SciSparc Ltd. as a high-risk, non-income asset suitable only for investors seeking exposure to early-stage biotechnology innovation rather than capital appreciation through dividends or consistent earnings growth.